Semaglutide vs Tirzepatide vs Retatrutide: What Actually Differs for a B2B Buyer
For a sourcing team, the meaningful differences between Semaglutide, Tirzepatide, and Retatrutide are not about which is "better." They come down to three sourcing realities: regulatory status (Semaglutide and Tirzepatide are approved, established compounds; Retatrutide is investigational and not approved as of 2026), molecular identity and complexity (they are three distinct molecules with different formulas, weights, and CAS numbers), and the documentation, QC depth, MOQ, lead time, and buyer-side compliance that follow from those two facts.
This guide compares the three strictly as sourced raw materials and lyophilized peptide vial projects. It does not compare end-market outcomes or buyer application fit, and it provides no product-use guidance of any kind. Each compound is treated only as a material you would document, quote, and procure — not as a finished product.
Identity at a Glance: Three Distinct Molecules, Three Documentation Profiles
The first thing to internalize is that these are not variants of one product. They are separate molecules, and a COA for one cannot be reasoned about using reference values for another.
| Attribute | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Developer code | — | LY3298176 | LY3437943 |
| CAS (free base) | 910463-68-2 | 2023788-19-2 | 2381089-83-2 |
| Molecular formula | C187H291N45O59 | C225H348N48O68 | C221H342N46O68 |
| Approx. molecular weight | ≈ 4113.6 g/mol | ≈ 4813.5 g/mol | ≈ 4731 g/mol |
| Sequence length | 31 amino acids | 39 amino acids | 39 amino acids (incl. non-standard residues) |
| Receptor-target class (classification only) | GLP-1 receptor agonist | Dual GIP / GLP-1 receptor agonist | Triple GIP / GLP-1 / glucagon receptor agonist |
| Regulatory status (2026) | Approved, established | Approved, established | Investigational — Phase 3, not approved |
Classification (single, dual, or triple incretin-receptor agonist) is included only as neutral category context to explain why these are distinct materials — not as any statement about performance or use. For sourcing, the practical signal is that molecular complexity rises across the three: larger formulas, more amino acids, and non-standard or lipidated residues mean more demanding synthesis, richer impurity profiles, and a correspondingly deeper documentation set that a careful buyer should expect.
The Decisive Difference Is Regulatory Status, Not the Molecule
If you remember one thing from this comparison, make it this: the molecules differ, but the regulatory status is what should reshape how you source.
Semaglutide and Tirzepatide are approved, established compounds. Their identity reference data is mature and public, so a buyer can benchmark a COA against well-documented values with confidence.
Retatrutide is different. As of 2026 it is investigational — in Phase 3 development and not approved by any regulator. That single fact changes the buyer side materially: how the material may be handled, what claims are permissible, how import and end-use are treated, and what your own compliance file must demonstrate are all different and generally more restrictive than for an approved compound.
This is a buyer-side compliance fact, not a quality judgment about the molecule. And it is precisely the kind of distinction that does not show up on a price line — which is why price is the wrong place to start.
What This Means for Documentation: COA, HPLC, and LC-MS
The documentation discipline is the same for all three, but the depth scales with complexity and status.
The three-document triangle still applies. For each compound, insist on a batch-level COA, an HPLC purity and related-substances report, and LC-MS or MS identity confirmation — all referencing the same batch number. A COA alone is a summary, not proof.
Identity is compound-specific. Each molecule has its own expected mass, so an MS report must match the correct reference for that compound. Confirm whether the reported mass is average or monoisotopic so you compare like with like, and sanity-check the stated formula and CAS against the identity table above.
Impurity profiles matter more as complexity rises. With Tirzepatide and Retatrutide, do not accept a headline main-peak percentage in isolation — ask for the single largest impurity, total related substances, and the method behind them.
Investigational status raises the bar on traceability. For Retatrutide especially, documentation completeness and batch traceability are not just quality niceties; they feed directly into your own buyer-side compliance position.
| Documentation focus | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Identity (MS mass match) | Mature public reference | Mature public reference | Verify against current reference; investigational |
| Purity / related substances | Scrutinize impurity data | Higher complexity — scrutinize closely | Higher complexity — scrutinize closely |
| Batch traceability | Standard expectation | Standard expectation | Elevated importance for compliance file |
| Buyer-side regulatory weight | Established pathway | Established pathway | More restrictive; confirm before sourcing |
Fill Format, MOQ, Lead Time — and Why Quotes Don't Compare Across the Three
Because these are three different molecules with different synthesis complexity and availability, a Semaglutide quote and a Retatrutide quote are not comparable as numbers, even before packaging enters the picture.
Even within a single compound, normalize every quote before comparing: convert per-vial, per-box, and per-gram pricing to one basis (usually cost per finished vial at the agreed fill), confirm the assay basis (free base vs salt), and match the document scope, packaging, and Incoterm.
Lead time is also not uniform across the three. More complex peptides and investigational compounds can carry different stock, QC-release, and lead-time realities. A supplier who can break lead time into stages — stock, testing, lyophilization, labeling, packaging — is one who actually controls the process. For material-specific review paths, see the Semaglutide vial B2B checklist, the Tirzepatide 60mg vial B2B checklist, and the Retatrutide vial B2B documentation checklist. The GHK-Cu sourcing guide also goes deeper on reading HPLC and COA documentation.
Buyer-Side Compliance: The Part You Cannot Outsource to a COA
Regulatory handling varies by market, intended use, product format, buyer role, and local rules — and this is sharpest where one of the three compounds is investigational.
Supplier documents support a sourcing decision. They do not replace buyer-side regulatory review. A complete COA package is necessary, not sufficient, for your own compliance position.
Buyers should confirm import, labeling, distribution, and end-use requirements in their own market, using their own regulatory resources or advisors — and should treat an investigational compound with particular care.
WUMO Peptide support is limited to B2B sourcing, documentation review, vial specification discussion, packaging coordination, and quotation preparation.
How to Run a Side-by-Side RFQ Across Semaglutide, Tirzepatide, and Retatrutide
Send each supplier the same structured request so the responses line up by compound:
- Exact name, developer code, and CAS for each compound (Semaglutide / Tirzepatide LY3298176 / Retatrutide LY3437943)
- Assay basis expected (free base / net peptide)
- Fill amount per vial
- Estimated quantities — sample and projected bulk, per compound
- Vial and packaging format
- Neutral label or private label / OEM
- Required documents — batch COA, HPLC, LC-MS/MS, SDS, specification sheet
- Destination market
- Regulatory-status acknowledgment for any investigational item, and confirmation of your own market's handling
- Expected lead time and shipping terms (Incoterm)
- Whether packaging or documentation support is needed
You can also browse current lyophilized peptide formats and review the quality and compliance context before moving into sample or bulk discussion.
WUMO Peptide can help B2B buyers review Semaglutide-, Tirzepatide-, and Retatrutide-related vial specifications, compare documentation scope, and prepare quotation discussions for lyophilized peptide vial projects. Start with our sample and documentation support path or request the files you need for review.
Related GLP-1 Sourcing Framework
For the broader sourcing framework behind this comparison, see the GLP-1 and incretin-related peptide sourcing guide.
Frequently Asked Questions
1. What is the main difference between Semaglutide, Tirzepatide, and Retatrutide for a B2B buyer?
Three things: classification (single, dual, and triple incretin-receptor agonists), regulatory status (the first two are approved and established; Retatrutide is investigational as of 2026), and the documentation and QC depth that follow. For sourcing, regulatory status and documentation matter more than the molecule itself.
2. Is Retatrutide approved?
No. As of 2026, Retatrutide (LY3437943) is investigational — in Phase 3 development and not approved by any regulator. That status carries buyer-side compliance implications that should be confirmed in your own market before sourcing.
3. Are Semaglutide and Tirzepatide the same kind of molecule?
No. They are distinct molecules with different formulas, molecular weights, and CAS numbers. Semaglutide is commonly classified as a GLP-1 receptor agonist; Tirzepatide as a dual GIP/GLP-1 receptor agonist. A COA for one cannot be checked against the other's reference values.
4. Can a buyer compare prices across the three directly?
No. They are different molecules with different synthesis complexity and availability, so cross-compound price comparison is not meaningful. Normalize within each compound first — per finished vial, on a stated assay basis, with matched documents and shipping terms.
5. What documents should come with any of these vials?
For each compound: a batch-level COA, an HPLC purity and related-substances report, LC-MS or MS identity confirmation, an SDS, and a specification sheet — all referencing the same batch number, ideally with batch traceability.
6. How does a buyer verify identity for each compound?
By matching the MS-measured mass to the correct reference for that specific compound, and sanity-checking the stated formula and CAS. Confirm whether the reported mass is average or monoisotopic so the comparison is valid.
7. Does molecular complexity affect the documentation a buyer should expect?
Yes. Larger, more complex peptides tend to carry richer impurity profiles, so scrutinize the single largest impurity, total related substances, and the test method — not just the headline purity percentage.
8. Can supplier documents replace buyer-side regulatory review?
No. Supplier documents support a sourcing decision, but regulatory handling varies by market, intended use, format, and buyer role. Buyers must confirm import, labeling, distribution, and end-use requirements in their own market — with particular care for any investigational compound.
9. Does WUMO Peptide provide end-use instructions?
No. WUMO Peptide support is limited to B2B sourcing, documentation review, vial specification discussion, packaging coordination, and quotation preparation.